Carcinoma, Squamous Cell: Clinical Trials

1107 completed, 540 recruiting, 440 unknown, 344 terminated. 1391 Phase 2, 785 Phase 1, 353 Not applicable, 304 Phase 3, 58 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	1391	Completed 468, Recruiting 253, Unknown 210, Terminated 165, Active not recruiting 133, Not yet recruiting 103, Withdrawn 52, Enrolling by invitation 5, Suspended 2
Phase 1	785	Completed 313, Recruiting 146, Terminated 140, Active not recruiting 71, Unknown 52, Withdrawn 36, Not yet recruiting 22, Enrolling by invitation 3, Suspended 2
Not applicable	353	Completed 121, Unknown 70, Recruiting 68, Not yet recruiting 27, Terminated 27, Active not recruiting 22, Withdrawn 13, Enrolling by invitation 4, Suspended 1
Phase 3	304	Completed 117, Recruiting 58, Unknown 41, Terminated 35, Active not recruiting 23, Not yet recruiting 18, Withdrawn 9, Enrolling by invitation 2, Suspended 1
Early Phase 1	58	Completed 21, Recruiting 12, Terminated 10, Unknown 5, Withdrawn 5, Active not recruiting 2, Not yet recruiting 2, Enrolling by invitation 1
Phase 4	19	Completed 8, Not yet recruiting 3, Unknown 3, Recruiting 2, Active not recruiting 1, Terminated 1, Withdrawn 1

Follow Carcinoma, Squamous Cell: new trials by email Literature Review of Carcinoma, Squamous Cell trials Research Report on Carcinoma, Squamous Cell

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab PANDA-VAC, Pembrolizumab - Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer	Phase 1	Suspended	UNC Lineberger Comprehensive Cancer Center	6	2027-05-20	2026-04-23
Chemo-embolization for Head and Neck Cancer Cisplatin - SCCHN, Squamous Cell Carcinoma	Phase 2	Withdrawn	University of Alabama at Birmingham		2027-05-01	2025-04-27
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma	Phase 1	Recruiting	National Cancer Institute (NCI)	39	2027-02-13	2026-09-03
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck Cemiplimab, Fianlimab, Carboplatin - Squamous Cell Carcinoma	Phase 2	Not yet recruiting	University of Chicago	90	2027-02-07	2026-01-20
Quad Shot Versus Split Course Radiotherapy in Incurable Head and Neck Cancer Quad Shot Radiotherapy, Split Course Radiotherapy - Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck	Not applicable	Not yet recruiting	Instituto Nacional de Cancerologia, Columbia	40	2027-01-01	2026-10-02
Bacterial Decolonization to Prevent Severe Radiation Dermatitis in Head and Neck Squamous Cell Carcinoma Bacterial decolonization, Standard Hygiene Measures - HNSCC	Not applicable	Not yet recruiting	Institut Cancerologie de l'Ouest	144	2027-01-01	2026-10-22
PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma	Phase 2	Not yet recruiting	Vanderbilt-Ingram Cancer Center	20	2026-12-31	2026-09-23
Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions TROP2 CAR/IL-15 TGFBR2 KO NK cells - Squamous Cell Carcinoma	Phase 1	Not yet recruiting	M.D. Anderson Cancer Center	36	2026-12-31	2026-06-11
Antitumor-B KAC PK Study Antitumor B KAC - Squamous Cell Carcinoma of the Oral Cavity	Phase 1	Withdrawn	Medical College of Wisconsin		2026-12-01	2025-03-18
Feasibility and Validation of an Automated AI-Enabled Deep Ultraviolet (DUV) Cytology Platform for Point-of-Care Oral Cancer Triage Deep UV-M and AI Cytology Triage - Oral Potentially Malignant Lesions, Oral Potentially Malignant Disorders	Not applicable	Not yet recruiting	Anh Le	270	2026-12-01	2026-09-25
Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) Pembroluzimab, Observation - HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma	Phase 2	Withdrawn	Dana-Farber Cancer Institute		2026-12-01	2026-10-08
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8	Phase 2	Not yet recruiting	Fred Hutchinson Cancer Center	50	2026-12-01	2026-09-17
Intralesional Chemotherapy (IC): Cisplatin + Epinephrine Cisplatin, Epinephrine injection, Laryngeal Biopsy - Laryngeal Squamous Cell Carcinoma	Phase 2	Recruiting	University of Miami	20	2026-12-01	2026-08-26
Screening Psychosocial Distress in Head and Neck Cancer Psychosocial distress screening using the Distress Thermometer - Head and Neck Cancer (H&N)		Not yet recruiting	Hôpital NOVO	80	2026-11-30	2026-10-01
Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva Tisotumab Vedotin - Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer	Phase 2	Not yet recruiting	GOG Foundation	28	2026-11-01	2026-06-29
Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial Ruxolitinib, Pembrolizumab - Carcinoma, Squamous Cell of Head and Neck HNSCC	Phase 2	Not yet recruiting	University Hospital, Basel, Switzerland	66	2026-11-01	2026-10-20
Optimizing Response to Immunotherapy With Online Adaptive Pulsed Radiotherapy in Incurable Head and Neck Cancers Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy - Head and Neck Squamous Cell Carcinoma (HNSCC)	Phase 2	Not yet recruiting	University Health Network, Toronto	48	2026-11-01	2026-10-22
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) - NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 1	Recruiting	Aktis Oncology, Inc.	152	2026-11-01	2026-10-22
CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma 64Cu-DOTA-ECL1i - Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)	Phase 2	Recruiting	Washington University School of Medicine	90	2026-10-31	2026-10-07
A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. LNTH-2403 - Imaging, Colorectal Cancer	Phase 1	Not yet recruiting	Radiopharm Theranostics, Ltd	16	2026-10-30	2026-08-12

Showing 20 of 3003. Sign in to see all of them.

Narrower conditions

Squamous Cell Carcinoma of Head and Neck (1946)  ·  Head and Neck Neoplasms (701)  ·  Esophageal Squamous Cell Carcinoma (622)  ·  Carcinoma, Non-Small-Cell Lung (359)  ·  Esophageal Neoplasms (248)  ·  Melanoma (222)  ·  Colorectal Neoplasms (162)  ·  Neoplasms (149)  ·  Neoplasm Metastasis (144)  ·  Mouth Neoplasms (133)  ·  Carcinoma, Renal Cell (130)  ·  Uterine Cervical Neoplasms (130)  ·  Stomach Neoplasms (128)  ·  Salivary Gland Neoplasms (126)

Broader conditions

Neoplasms by Histologic Type (2999)  ·  Neoplasms, Glandular and Epithelial (2997)  ·  Carcinoma (2902)  ·  Neoplasms (2854)  ·  Neoplasms by Site (2816)  ·  Head and Neck Neoplasms (1989)  ·  Neoplasms, Squamous Cell (1219)  ·  Digestive System Diseases (934)  ·  Digestive System Neoplasms (911)  ·  Gastrointestinal Diseases (905)  ·  Gastrointestinal Neoplasms (879)  ·  Esophageal Diseases (716)  ·  Respiratory Tract Diseases (515)  ·  Respiratory Tract Neoplasms (481)

Interventions

Cisplatin (455)  ·  Radiotherapy (293)  ·  pembrolizumab (292)  ·  Cetuximab (210)  ·  Paclitaxel (199)  ·  Carboplatin (195)  ·  Fluorouracil (175)  ·  Docetaxel (164)  ·  Radiotherapy, Intensity-Modulated (108)  ·  Nivolumab (107)  ·  Drug Therapy (85)  ·  Radiation (66)  ·  Surgical Procedures, Operative (55)  ·  tislelizumab (53)  ·  130-nm albumin-bound paclitaxel (50)

Sponsors

National Cancer Institute (NCI) (88)  ·  M.D. Anderson Cancer Center (55)  ·  Sun Yat-sen University (46)  ·  Fudan University (45)  ·  Memorial Sloan Kettering Cancer Center (45)  ·  Dana-Farber Cancer Institute (30)  ·  Vanderbilt-Ingram Cancer Center (28)  ·  Radiation Therapy Oncology Group (27)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (27)  ·  Washington University School of Medicine (24)  ·  Roswell Park Cancer Institute (23)  ·  Tianjin Medical University Cancer Institute and Hospital (23)  ·  Merck Sharp & Dohme LLC (22)  ·  University Health Network, Toronto (22)  ·  Groupe Oncologie Radiotherapie Tete et Cou (21)

Countries

United States (1401)  ·  China (648)  ·  France (293)  ·  Canada (199)  ·  Spain (198)  ·  United Kingdom (185)  ·  Italy (160)  ·  South Korea (156)  ·  Taiwan (153)  ·  Germany (149)  ·  Australia (132)  ·  Belgium (132)  ·  Japan (101)  ·  Netherlands (96)  ·  Poland (78)

Top investigators

Barbara Murphy, MD (10)  ·  David H. Ilson, MD, PhD (8)  ·  Yuankai Shi, MD (8)  ·  Douglas Adkins, M.D. (7)  ·  Douglas R Adkins, M.D. (7)  ·  Corey J. Langer, MD (6)

Results publications

PMID 25057165, PMID 33538338, PMID 36990609, PMID 17960012, PMID 25081901, PMID 25979390, PMID 26254683, PMID 30089078, PMID 31420360, PMID 31679945, PMID 32665297, PMID 33373868, PMID 41309527, PMID 41343184, PMID 15128893, PMID 15128894, PMID 16161069, PMID 16467544, PMID 18309943, PMID 18784101, PMID 19465425, PMID 19557750, PMID 20530316, PMID 21684205, PMID 22749632, PMID 22960745, PMID 23996343, PMID 24982463, PMID 26808342, PMID 27718784, PMID 28742685, PMID 30509740, PMID 30548235, PMID 30944020, PMID 32017652, PMID 33243986, PMID 33300372, PMID 33605440, PMID 33720067, PMID 34160577, PMID 34454674, PMID 35091445, PMID 35440464, PMID 36897458, PMID 36923556, PMID 38710003, PMID 39489541, PMID 40373876, PMID 40467307, PMID 40511820

NIH funding

2023 (39), 2019 (21), 2017 (16), 2018 (15), U10CA032102 (15), 2016 (13), P30CA068485 (13), 2014 (12), 2015 (10), P30CA012197 (10), 2025 (9), P30CA043703 (9), U10CA021115 (9), U10CA180868 (9), U10CA180820 (8)